Key result
L-carnitine yields ~3.5-fold higher odds of clinical efficacy in chronic heart failure, but does not cut mortality.
Why the study?
Does L-carnitine treatment improve clinical efficacy, cardiac function, and survival in patients with chronic heart failure?
Meta-Analysis (n=1,625)
3 studies used blind method; blind methods of all other 14 studies were unclear
Randomized controlled trials (4 did not report method; others used randomization number sequence or adaptive minimization randomization scheme)
Yes
Does L-carnitine treatment improve clinical efficacy, cardiac function, and survival in patients with chronic heart failure?
Adjuvant L-carnitine therapy in chronic heart failure patients is well-tolerated and associated with improvements in NYHA functional class, echocardiographic parameters, and natriuretic peptide levels, though it does not significantly reduce all-cause mortality or 6-minute walk distance.
Answers are grounded in this paper and cite their sources.
L-carnitine improves clinical efficacy and LVEF without mortality benefit in chronic HF; extends RCT evidence but leaves survival effect unresolved.
Background . Whether additional benefit can be achieved with the use of L-carnitine (L-C) in patients with chronic heart failure (CHF) remains controversial. We therefore performed a meta-analysis of randomized controlled trials (RCTs) to evaluate the effects of L-C treatment in CHF patients. Methods . Pubmed, Ovid Embase, Web of Science, and Cochrane Library databases, Chinese National Knowledge Infrastructure (CNKI) database, Wanfang database, Chinese Biomedical (CBM) database, and Chinese Science and Technology Periodicals database (VIP) until September 30, 2016, were identified. Studies that met the inclusion criteria were systematically evaluated by two reviewers independently. Results . 17 RCTs with 1625 CHF patients were included in this analysis. L-C treatment in CHF was associated with considerable improvement in overall efficacy (OR = 3.47, P < 0.01 ), left ventricular ejection fraction (LVEF) (WMD: 4.14%, P = 0.01 ), strike volume (SV) (WMD: 8.21 ml, P = 0.01 ), cardiac output (CO) (WMD: 0.88 L/min, P < 0.01 ), and E/A (WMD: 0.23, P < 0.01 ). Moreover, treatment with L-C also resulted in significant decrease in serum levels of BNP (WMD: −124.60 pg/ml, P = 0.01 ), serum levels of NT-proBNP (WMD: −510.36 pg/ml, P < 0.01 ), LVESD (WMD: −4.06 mm, P < 0.01 ), LVEDD (WMD: −4.79 mm, P < 0.01 ), and LVESV (WMD: −20.16 ml, 95% CI: −35.65 to −4.67, P < 0.01 ). However, there were no significant differences in all-cause mortality, 6-minute walk, and adverse events between L-C and control groups. Conclusions . L-C treatment is effective for CHF patients in improving clinical symptoms and cardiac functions, decreasing serum levels of BNP and NT-proBNP. And it has a good tolerance.
No takes yet. Share an insight, caveat, or question.
Song et al. (2017) conducted a meta-analysis in Chronic heart failure (n=1,625). L-carnitine vs. Placebo, routine, or conventional treatment was evaluated on Overall efficacy (improvement in cardiac function defined as a decrease of at least one NYHA class) (OR 3.47, 95% CI 2.49 to 4.82, p=<0.01). L-carnitine improved overall clinical efficacy and LVEF in chronic heart failure patients without reducing all-cause mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: